drugset / Trial / NCT07190300
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of the study is to evaluate the safety, tolerability, and efficacy of the two different treatment combinations of tulmimetostat in participants with de novo or recurrent Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).
Timeline
- Start
- 2026-01-13
- Primary completion
- 2032-08-02
- Completion
- 2032-08-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | 1000 mg | Oral |
| Subject | Darolutamide | Other / unclassified | 600 mg | Oral |
| Subject | Tulmimetostat | Small molecule | — | Oral |